Arovella Therapeutics ASX: ALA

Arovella Therapeutics ASX: ALA Arovella Therapeutics is a biotechnology company focused on developing its unique iNKT cell therapy platform to treat cancer.

CAR-iNKT CELL PLATFORM DATA PRESENTED AT ASH Highlights include:• Superior animal survival data from Arovella’s CAR-iNKT...
10/12/2023

CAR-iNKT CELL PLATFORM DATA PRESENTED AT ASH

Highlights include:

• Superior animal survival data from Arovella’s CAR-iNKT Platform with CD28 co-stimulatory domain;

• New data utilising a different CAR-iNKT model on Arovella’s platform supports the extended use of the CAR-iNKT cell platform against multiple tumour types;

• Data presented at the 65th American Society of Hematology (ASH) annual meeting.

More at Arovella.com

04/12/2023

The iNKT Cell Therapy Revolution

In this video, we are going to explain what cell therapy is, and in particular, invariant natural killer T (i-N-K-T) cell therapy — in combination with CARs (chimeric antigen receptors).

After watching this video, you will be able to explain the ‘cell therapy revolution’ and grasp its future potential in the fight against cancer.

Welcome to Arovella Therapeutics ASX: ALA - at the time of making this video, we are the only Australian biotech company developing an iNKT cell therapy platform. Our core focus is on developing therapies to treat cancers.

Our December 2023 Newsletter is now available atarovella.com/newsletters• Letter from the Chair;• Progress on ALA-101;• ...
04/12/2023

Our December 2023 Newsletter is now available at
arovella.com/newsletters

• Letter from the Chair;

• Progress on ALA-101;

• Expanding into solid tumours;

• Introducing ALA-105;

• Cytokine technology enhances iNKT cell platform;

• New explanatory whiteboard video & Instagram
account: https://www.instagram.com/wearearovella/ and more...

ASX NEWS:AGM Chairman's Address and CEO & MD PresentationDownload at arovella.com/asx-announcements
10/11/2023

ASX NEWS:
AGM Chairman's Address and CEO & MD Presentation

Download at arovella.com/asx-announcements

We are pleased to announce that our CEO and MD, Dr Michael Baker, will today present at the Capital Network’s Emerging A...
02/11/2023

We are pleased to announce that our CEO and MD, Dr Michael Baker, will today present at the Capital Network’s Emerging ASX Gems conference.

Dr Baker will provide an overview of Arovella’s iNKT cell therapy platform and how the technology provides important advantages over existing T-cell therapies and has the potential to be applied to both blood cancers and solid tumours.

arovella.com/investor-presentations

Address

84 Hotham Street, Preston
Melbourne, VIC
3072

Website

Alerts

Be the first to know and let us send you an email when Arovella Therapeutics ASX: ALA posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Featured

Share